bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods, Supplementary References, Supplementary Tables 1-3, Supplementary Figures 1-4 from Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Authors: Kohli Manish , Ho Yeung , Hillman David W. , Van Etten Jamie L. , Henzler Christine , Yang Rendong , Sperger Jamie M. , Li Yingming , Tseng Elizabeth , Hon Ting , Clark Tyson , Tan Winston , Carlson Rachel E. , Wang Liguo , Sicotte Hugues , Thai Ho , Jimenez Rafael , Huang Haojie , Vedell Peter T. , Eckloff Bruce W. , Quevedo Jorge F. , Pitot Henry C. , Costello Brian A. , Jen Jin , Wieben Eric D. , Silverstein Kevin A.T. , Lang Joshua M. , Wang Liewei , Dehm Scott M.
Published: April 2023

Supplementary Table 1: Baseline Characteristics of the Patients; Supplementary Table 2: Baseline RNA-seq Expression Levels for AR/ARVs (spliced reads per million); Supplementary Table 3: TaqMan Gene Expression Assays with Circulating Tumor Cells; Supplementary Figure 1: Actinomycin D responses of AR-V9 and AR-V7 mRNA in 22Rv1 cells; Supplementary Figure 2: 3â€™ rapid amplification of cDNA ends (RACE) for single molecule real-time (SMRT) sequencing; Supplementary Figure 3: Purified AR-V9 polyclonal antibodies detect overexpressed AR-V9 in western blot with overexpressed AR-V9; Supplementary Figure 4: Relationship between tumor RNA p13 purity, AR-V7, and AR-V9 expression levels in CRPC metastases.
Supplementary Figures 1-5 and Supplementary Table 1 from Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Authors: Carlsten Mattias , Korde Neha , Kotecha Ritesh , Reger Robert , Bor Simona , Kazandjian Dickran , Landgren Ola , Childs Richard W.
Published: April 2023

Supplementary Figure 1. Outline of the open-label single arm two-stage phase II clinical trial evaluating single agent IPH2101 in patients with smoldering multiple myeloma; Supplementary Figure 2. Absolute NK-cell counts in peripheral blood following infusion of IPH2101 in patients with smoldering multiple myeloma; Supplementary Figure 3. IPH2101 does not affect the viability of KIR2D+ cells; Supplementary Figure 4. Loss of KIR2D molecules on the NK-cell surface following IPH2101-induced trogocytosis; Supplementary Figure 5. IL-2 activation of patient NK-cells ex vivo significantly increases baseline cytotoxic function; Supplementary Table 1. Patient and disease characteristics, response at end of trial and disease status at last evaluable follow-up point.
Figure S8 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Authors: Casillas Andrea L. , Toth Rachel K. , Sainz Alva G. , Singh Neha , Desai Ankit A. , Kraft Andrew S. , Warfel Noel A.
Published: April 2023

Metastases arising from prostate tumors show significant regions of hypoxia
Supplementary Figures S1 - S6 from Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
Authors: Au-Yeung George , Lang Franziska , Azar Walid J. , Mitchell Chris , Jarman Kate E. , Lackovic Kurt , Aziz Diar , Cullinane Carleen , Pearson Richard B. , Mileshkin Linda , Rischin Danny , Karst Alison M. , Drapkin Ronny , Etemadmoghadam Dariush , Bowtell David D.L.
Published: April 2023

Supplementary Figure S1 - Validation of CCNE1 and CDK2 siRNA-mediated knockdown Supplementary Figure S2 - Validation of CDK2 knockdown mediated by shRNA in vitro and in vivo Supplementary Figure S3 - FACS plots validating incorporation and induction of shRNA into OVCAR3 and CAOV3 cells Supplementary Figure S4 - Characterisation of CDK resistant lines and supplementary data supporting drug treatment Supplementary Figure S5 - Extended Oncoprint figure from TCGA Supplementary Figure S6 - Validation of FT282 over-expression constructs
Figure S6 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Authors: Casillas Andrea L. , Toth Rachel K. , Sainz Alva G. , Singh Neha , Desai Ankit A. , Kraft Andrew S. , Warfel Noel A.
Published: April 2023

Loss of PIM blunts hypoxia-induced stabilization of HIF-1/2 and the expression of HIF-1 target genes
Figure S4 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Authors: Casillas Andrea L. , Toth Rachel K. , Sainz Alva G. , Singh Neha , Desai Ankit A. , Kraft Andrew S. , Warfel Noel A.
Published: April 2023

Combinatorial inhibition of PIM and VEGF produces synergistic anti-tumor activity in xenograft models of prostate and colon cancer
Figure S4 from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Authors: Gainor Justin F. , Shaw Alice T. , Sequist Lecia V. , Fu Xiujun , Azzoli Christopher G. , Piotrowska Zofia , Huynh Tiffany G. , Zhao Ling , Fulton Linnea , Schultz Katherine R. , Howe Emily , Farago Anna F. , Sullivan Ryan J. , Stone James R. , Digumarthy Subba , Moran Teresa , Hata Aaron N. , Yagi Yukako , Yeap Beow Y. , Engelman Jeffrey A. , Mino-Kenudson Mari
Published: April 2023

Quantitative image-based CD8+ TILs in baseline specimens of EGFR-mutant versus KRAS-mutant patients.
Figure S2 from Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Authors: Casillas Andrea L. , Toth Rachel K. , Sainz Alva G. , Singh Neha , Desai Ankit A. , Kraft Andrew S. , Warfel Noel A.
Published: April 2023

PIM1 expressing tumors maintain vasculature during treatment with anti-angiogenic agents
Figure S1 from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Authors: Gainor Justin F. , Shaw Alice T. , Sequist Lecia V. , Fu Xiujun , Azzoli Christopher G. , Piotrowska Zofia , Huynh Tiffany G. , Zhao Ling , Fulton Linnea , Schultz Katherine R. , Howe Emily , Farago Anna F. , Sullivan Ryan J. , Stone James R. , Digumarthy Subba , Moran Teresa , Hata Aaron N. , Yagi Yukako , Yeap Beow Y. , Engelman Jeffrey A. , Mino-Kenudson Mari
Published: April 2023

PD-L1 expression in FFPE samples with anti-PD-L1 antibody (clone E1L3N): A) Positive control (HDLM2 cell line with known PD-L1 expression). B) Negative control (PC3 cell line).
Supplementary Data from Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
Authors: Mostaghel Elahe A. , Cho Eunpi , Zhang Ailin , Alyamani Mohammad , Kaipainen Arja , Green Sean , Marck Brett T. , Sharifi Nima , Wright Jonathan L. , Gulati Roman , True Lawrence D. , Loda Massimo , Matsumoto Alvin M. , Tamae Daniel , Penning Trevor N. , Balk Steven P. , Kantoff Phillip W. , Nelson Peter S. , Taplin Mary-Ellen , Montgomery R. Bruce
Published: April 2023

Supplementary Figures and Tables Supplementary Table S1. Baseline Patient Demographic and Clinical Characteristics Supplementary Table S2. Observed and Expected Hardy Weinberg (HW) Frequency of SLCO Genotypes Supplementary Table S3. Distribution of Men with Undetectable Tissue ABI Levels Supplementary Table S4. Characteristics of SLCO Genotypes and Potential Prostate Cancer Associations Supplementary Table S5. Association of SLCO Genotype with Tissue Abiraterone, Estimated Tumor Volume and Minimal Residual Disease (MRD) Supplementary Figure S1. Representative chromatograms showing retention time for abiraterone standard and tissue samples. Supplementary Figure S2. Serum steroid levels in samples with undetectable vs detectable prostate abiraterone levels. Supplementary Figure S3. Association of SLCO single nucleotide polymorphisms with serum or tissue steroid levels. Supplementary Figure S4. Absolute abiraterone levels measured in LNCaP cells overexpressing SLCO2B1 or SLCO1B3.
Supplementary Table S1 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas
Authors: Remacha Laura , Comino-Méndez Iñaki , Richter Susan , Contreras Laura , Currás-Freixes María , Pita Guillermo , Letón Rocío , Galarreta Antonio , Torres-Pérez Rafael , Honrado Emiliano , Jiménez Scherezade , Maestre Lorena , Moran Sebastian , Esteller Manel , Satrústegui Jorgina , Eisenhofer Graeme , Robledo Mercedes , Cascón Alberto
Published: April 2023

Genes included in the targeted next-generation sequencing panel
Supplemental Figure 9 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Cell viability of human GBM cells in response to different doses of hIFNÃŽÂ²
Supplemental Figure 7 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Engineering cells expressing secretory mouse and human IFNÃŽÂ²
Supplementary Figure Legends from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas
Authors: Remacha Laura , Comino-Méndez Iñaki , Richter Susan , Contreras Laura , Currás-Freixes María , Pita Guillermo , Letón Rocío , Galarreta Antonio , Torres-Pérez Rafael , Honrado Emiliano , Jiménez Scherezade , Maestre Lorena , Moran Sebastian , Esteller Manel , Satrústegui Jorgina , Eisenhofer Graeme , Robledo Mercedes , Cascón Alberto
Published: April 2023

Legends of the Supplementary Figures
Supplemental Figure 11 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Cell cycle response of GBM4 to hIFNÃŽÂ²
Supplementary Table 1 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Authors: Wood Andrew C. , Krytska Kateryna , Ryles Hannah T. , Infarinato Nicole R. , Sano Renata , Hansel Theodore D. , Hart Lori S. , King Frederick J. , Smith Timothy R. , Ainscow Edward , Grandinetti Kathryn B. , Tuntland Tove , Kim Sunkyu , Caponigro Giordano , He You Qun , Krupa Shiva , Li Nanxin , Harris Jennifer L. , Mossé Yaël P.
Published: April 2023

Neuroblastoma cell line characteristics and Combination Index values in validation panel.
Supplementary methods and Figures from The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
Authors: Blunt Matthew D. , Koehrer Stefan , Dobson Rachel C. , Larrayoz Marta , Wilmore Sarah , Hayman Alice , Parnell Jack , Smith Lindsay D. , Davies Andrew , Johnson Peter W.M. , Conley Pamela B. , Pandey Anjali , Strefford Jonathan C. , Stevenson Freda K. , Packham Graham , Forconi Francesco , Coffey Greg P. , Burger Jan A. , Steele Andrew J.
Published: April 2023

Supplementary methods and Figures Supplementary Figure 1. Effect of cerdulatinib on Immobilised anti-IgM mediated signaling Supplementary Figure 2. Effect of cerdulatinib on soluble anti-IgM mediated signaling Supplementary Figure 3. Effect of cerdulatinib on Immobilised anti-IgD mediated signaling Supplementary Figure 4. Effect of cerdulatinib on soluble anti-IgD mediated signaling Supplementary Figure 5. Effect of cerdulatinib on anti-IgM induced calcium flux and IL-4 induced surface marker expression Supplementary Figure 6. Representative phosflow plots Supplementary Figure 7. Cerdulatinib overcomes the protective effect of BCR-stimulation and IL- 4/CD40L. Supplementary Figure 8. Mcl-1 and Bcl-XL but not Bcl-2 are downregulated by cerdulatinib Supplementary Figure 9. Effect of cerdulatinib on MCL-1 and BCL-XL mRNA expression
Supplementary Figure Legend from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Authors: Wood Andrew C. , Krytska Kateryna , Ryles Hannah T. , Infarinato Nicole R. , Sano Renata , Hansel Theodore D. , Hart Lori S. , King Frederick J. , Smith Timothy R. , Ainscow Edward , Grandinetti Kathryn B. , Tuntland Tove , Kim Sunkyu , Caponigro Giordano , He You Qun , Krupa Shiva , Li Nanxin , Harris Jennifer L. , Mossé Yaël P.
Published: April 2023

Supplementary Figure Legend
Supplementary Figure 4 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Authors: Wood Andrew C. , Krytska Kateryna , Ryles Hannah T. , Infarinato Nicole R. , Sano Renata , Hansel Theodore D. , Hart Lori S. , King Frederick J. , Smith Timothy R. , Ainscow Edward , Grandinetti Kathryn B. , Tuntland Tove , Kim Sunkyu , Caponigro Giordano , He You Qun , Krupa Shiva , Li Nanxin , Harris Jennifer L. , Mossé Yaël P.
Published: April 2023

Overview of compound activity by cell line.
Supplementary Figure 3 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Authors: Wood Andrew C. , Krytska Kateryna , Ryles Hannah T. , Infarinato Nicole R. , Sano Renata , Hansel Theodore D. , Hart Lori S. , King Frederick J. , Smith Timothy R. , Ainscow Edward , Grandinetti Kathryn B. , Tuntland Tove , Kim Sunkyu , Caponigro Giordano , He You Qun , Krupa Shiva , Li Nanxin , Harris Jennifer L. , Mossé Yaël P.
Published: April 2023

Impact of ALK and CDK4 knockdown in NB-1691.
Supplementary Materials and Methods from Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients
Authors: Gannon Philippe O. , Baumgaertner Petra , Huber Alexandre , Iancu Emanuela M. , Cagnon Laurène , Abed Maillard Samia , Maby-El Hajjami Hélène , Speiser Daniel E. , Rufer Nathalie
Published: April 2023

Supplementary FACS and sorting procedures
Table S5 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Authors: Patel Sohil H. , Poisson Laila M. , Brat Daniel J. , Zhou Yueren , Cooper Lee , Snuderl Matija , Thomas Cheddhi , Franceschi Ana M. , Griffith Brent , Flanders Adam E. , Golfinos John G. , Chi Andrew S. , Jain Rajan
Published: April 2023

RPPA results comparing protein levels between the IDHmut-Noncodel gliomas from the TCGA/TCIA cohort differentiated by the T2-FLAIR mismatch sign.
Supplementary Data from TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
Authors: Labbé David P. , Sweeney Christopher J. , Brown Myles , Galbo Phillip , Rosario Spencer , Wadosky Kristine M. , Ku Sheng-Yu , Sjöström Martin , Alshalalfa Mohammed , Erho Nicholas , Davicioni Elai , Karnes R. Jeffrey , Schaeffer Edward M. , Jenkins Robert B. , Den Robert B. , Ross Ashley E. , Bowden Michaela , Huang Ying , Gray Kathryn P. , Feng Felix Y. , Spratt Daniel E. , Goodrich David W. , Eng Kevin H. , Ellis Leigh
Published: April 2023

Supplement Materials and Methods and Figures S1-S6 Supplement Figure 1: Taylor et al. (2010) data indicate that concurrent TOP2A and EZH2 expression identify primary PCa patients with a more aggressive disease. Supplement Figure 2: GSEA for oncogenic signatures in primary human PCa revealed statistically significant overlapping for gene signatures involving VEGF and E2F1 signaling from the TCGA (2015) and Taylor et al. (2010) datasets. (P < 0.05 and FDR < 0.15; Supplement Table 3). Supplement Figure 3: Genes that have been demonstrated to be up-regulated in indolent primary PCa are down regulated in TCGA (2015) patients with concurrent up-regulation of TOP2A and EZH2 (TOP2A+/EZH2+) (Mann-Whitney; * P < 0.05; *** P < 0.001). Supplement Figure 4: Concurrent high TOP2A and EZH2 expression in primary prostatic tumors (TOP2A+/EZH2+) is not associated to a shorter time to biochemical recurrence when compared to TOP2A-/EZH2- patients included in the (A) Mayo Clinic Validation study, (B) Thomas Jefferson University dataset or the (C) Johns Hopkins University post-RP dataset. Supplement Figure 5: (A) Combination therapy induces loss of clonogenicity specific to dKO cells (top: representative experiment; unpaired t test; ** P < 0.01, triplicate, mean {plus minus}SEM). (B) Cell cycle analysis indicates that combination therapy targeting both EZH2 (GSK126 or EPZ6438, 5 μM) and TOP2A (Etoposide, 1 μM) induces G2M arrest in both sKO and dKO cell lines but results in a significant increase in apoptosis as indicated by SubG1 accumulation only in dKO (unpaired t test; ** P < 0.01, triplicate, mean {plus minus}SEM). Supplement Figure 6: TOP2A and EZH2 co-expression can select for metastatic disease progression and shorter regression-free survival in the TCGA's (A) Clear Renal Cell Carcinoma and the (B) Papillary Kidney Carcinoma datasets. (Abbreviations: no distant metastasis, M0; distant metastasis, M1)
Figure S1-S12 from Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib
Authors: Li Chien-Feng , Fang Fu-Min , Chen Yen-Yang , Liu Ting-Ting , Chan Ti-Chun , Yu Shih-Chen , Chen Li-Tzong , Huang Hsuan-Ying
Published: April 2023

Supplementary Figure S1-S12
Supplementary Figure 3 from In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Authors: Osada Takuya , Kaneko Kensuke , Gwin William R. , Morse Michael A. , Hobeika Amy , Pogue Brian W. , Hartman Zachary C. , Hughes Philip F. , Haystead Timothy , Lyerly H. Kim
Published: April 2023

NIR Imaging of Intraductally and Subcutaneously Implanted 4T1 cells
Supplementary Figure S1 from Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials
Authors: Coleman C. Norman , Higgins Geoff S. , Brown J. Martin , Baumann Michael , Kirsch David G. , Willers Henning , Prasanna Pataje G.S. , Dewhirst Mark W. , Bernhard Eric J. , Ahmed Mansoor M.
Published: April 2023

Illustration of utility of companion canine spontaneous cancer model to address the complexities in preclinical in vivo radiobiological assays
Figure S4 from Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Authors: Jiao Hong-Li , Ye Ya-Ping , Yang Run-Wei , Sun Hui-Ying , Wang Shu-Yang , Wang Yong-Xia , Xiao Zhi-Yuan , He Liu-Qing , Cai Juan-Juan , Wei Wen-Ting , Chen Yan-Ru , Gu Chun-Cai , Cai Yue-Long , Hu Yun-Teng , Lai Qiu-Hua , Qiu Jun-Feng , Liang Li , Cao Guang-Wen , Liao Wen-Ting , Ding Yan-Qing
Published: April 2023

Figure S4 shows that down-regulation of SAFB contributed to the aggressive features of CRC cells through the SAFB-TAK1-NF-κB axis.
Supplementary Figure S1-S9 from FUS–DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma
Authors: Trautmann Marcel , Menzel Jasmin , Bertling Christian , Cyra Magdalene , Isfort Ilka , Steinestel Konrad , Elges Sandra , Grünewald Inga , Altvater Bianca , Rossig Claudia , Fröhling Stefan , Hafner Susanne , Simmet Thomas , Åman Pierre , Wardelmann Eva , Huss Sebastian , Hartmann Wolfgang
Published: April 2023

Supplementary Figure (S1): Activation of the IGF-IR and PI3K/Akt/GSK-3beta signaling cascade in representative myxoid liposarcoma cell lines. (S2): Representative sequencing results of PIK3CA mutation hotspots. (S3): IGF-II-effected rescue of PI3K/Akt/GSK-3beta pathway activation in FUS-DDIT3 depleted myxoid liposarcoma cells. (S4): RNAi-mediated reduction of FUS-DDIT3 oncoprotein levels. (S5): Expression and activation levels of IGF-IR and PI3K/Akt/GSK-3beta signaling effectors in A673 and Capan-1 cells. (S6): In vitro and in vivo evaluation of PPP in MLS cells. (S7): Time dependent reduction of Cyclin D1 protein levels. (S8): Flow cytometric analyses in MLS1765-92 cells. (S9): Representative CAM explants (NVP AEW541, MLS402-91 cells).
Figure S1 from Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Authors: Jiao Hong-Li , Ye Ya-Ping , Yang Run-Wei , Sun Hui-Ying , Wang Shu-Yang , Wang Yong-Xia , Xiao Zhi-Yuan , He Liu-Qing , Cai Juan-Juan , Wei Wen-Ting , Chen Yan-Ru , Gu Chun-Cai , Cai Yue-Long , Hu Yun-Teng , Lai Qiu-Hua , Qiu Jun-Feng , Liang Li , Cao Guang-Wen , Liao Wen-Ting , Ding Yan-Qing
Published: April 2023

Figure S1 shows that expression of SAFB in public databases and human CRC tissue
'Table S1' from Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
Authors: Cooper Wendy A. , Russell Prudence A. , Cherian Maya , Duhig Edwina E. , Godbolt David , Jessup Peter J. , Khoo Christine , Leslie Connull , Mahar Annabelle , Moffat David F. , Sivasubramaniam Vanathi , Faure Celine , Reznichenko Alena , Grattan Amanda , Fox Stephen B.
Published: April 2023

'Table S1 shows agreement with the gold standard at 50% cut-point for each participating pathologists.'
Supplementary Table S3 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Authors: Pereira Carolina , Gimenez-Xavier Pol , Pros Eva , Pajares Maria J. , Moro Massimo , Gomez Antonio , Navarro Alejandro , Condom Enric , Moran Sebastian , Gomez-Lopez Gonzalo , Graña Osvaldo , Rubio-Camarillo Miriam , Martinez-Martí Alex , Yokota Jun , Carretero Julian , Galbis Jose M. , Nadal Ernest , Pisano David , Sozzi Gabriella , Felip Enriqueta , Montuenga Luis M. , Roz Luca , Villanueva Alberto , Sanchez-Cespedes Montse
Published: April 2023

Supplementary Table S3
Supplementary Table S2 from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Proteins identified in cyst fluid samples.
Supplementary Figure S1-S9. from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Figures supporting our finding of increased aspartyl protease activity in mucinous pancreatic cysts.
Supplemental Methods and Materials from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Detailed description of peptide synthesis and proteomic search parameters for cyst fluid samples.
Supplemental Figure 7 from Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Authors: Carew Jennifer S. , Espitia Claudia M. , Zhao William , Han Yingchun , Visconte Valeria , Phillips James , Nawrocki Steffan T.
Published: April 2023

ROC-325 combination data.
Supplemental Figure 5 from Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Authors: Carew Jennifer S. , Espitia Claudia M. , Zhao William , Han Yingchun , Visconte Valeria , Phillips James , Nawrocki Steffan T.
Published: April 2023

Drug washout experiment.
Supplemental Figure 4 from Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Authors: Carew Jennifer S. , Espitia Claudia M. , Zhao William , Han Yingchun , Visconte Valeria , Phillips James , Nawrocki Steffan T.
Published: April 2023

Cathepsin D knockdown studies.
Supplemental Figure 2 from Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Authors: Carew Jennifer S. , Espitia Claudia M. , Zhao William , Han Yingchun , Visconte Valeria , Phillips James , Nawrocki Steffan T.
Published: April 2023

Supplemental Figure 2. High Res Mass Spec of ROC-325
Table S3 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Authors: Erbe Amy K. , Wang Wei , Carmichael Lakeesha , Kim KyungMann , Mendonça Eneida A. , Song Yiqiang , Hess Dustin , Reville Patrick K. , London Wendy B. , Naranjo Arlene , Hank Jacquelyn A. , Diccianni Mitchell B. , Reisfeld Ralph A. , Gillies Stephen D. , Matthay Katherine K. , Cohn Susan L. , Hogarty Michael D. , Maris John M. , Park Julie R. , Ozkaynak M. Fevzi , Gilman Andrew L. , Yu Alice L. , Sondel Paul M.
Published: April 2023

Genotype categories discussed in manuscript.
Supplementary Figure S6 from Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Authors: Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Mesiano Giulia , Rotolo Ramona , Sassi Francesco , Sanlorenzo Martina , Zaccagna Alessandro , Pisacane Alberto , Senetta Rebecca , Cangemi Michela , Cattaneo Giulia , Martin Valentina , Coha Valentina , Gallo Susanna , Pignochino Ymera , Sapino Anna , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Supplementary Figure S6: Sequential chemo-immunotherapy associates with improved survival
Figure S4 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Authors: Neven Patrick , Jongen Lynn , Lintermans Anneleen , Van Asten Kathleen , Blomme Chantal , Lambrechts Diether , Poppe An , Wildiers Hans , Dieudonné Anne-Sophie , Brouckaert Olivier , Decloedt Jan , Berteloot Patrick , Verhoeven Didier , Joerger Markus , Vuylsteke Peter , Wynendaele Wim , Casteels Minne , Van Huffel Sabine , Lybaert Willem , Van Ginderachter Johan , Paridaens Robert , Vergote Ignace , Dezentjé Vincent Olaf , Van Calster Ben , Guchelaar Henk-Jan
Published: April 2023

Kaplan-Meier curves stratified by endoxifen levels using a quartile split.
Supplementary Figure S3 from Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Authors: Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Mesiano Giulia , Rotolo Ramona , Sassi Francesco , Sanlorenzo Martina , Zaccagna Alessandro , Pisacane Alberto , Senetta Rebecca , Cangemi Michela , Cattaneo Giulia , Martin Valentina , Coha Valentina , Gallo Susanna , Pignochino Ymera , Sapino Anna , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Supplementary Figure S3:Expression of NKG2D ligands and PDL1 on putative mCSCs following different treatments.
Figure S1 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Authors: Neven Patrick , Jongen Lynn , Lintermans Anneleen , Van Asten Kathleen , Blomme Chantal , Lambrechts Diether , Poppe An , Wildiers Hans , Dieudonné Anne-Sophie , Brouckaert Olivier , Decloedt Jan , Berteloot Patrick , Verhoeven Didier , Joerger Markus , Vuylsteke Peter , Wynendaele Wim , Casteels Minne , Van Huffel Sabine , Lybaert Willem , Van Ginderachter Johan , Paridaens Robert , Vergote Ignace , Dezentjé Vincent Olaf , Van Calster Ben , Guchelaar Henk-Jan
Published: April 2023

Quality of Life Questionnaire
Supplementary Experimental Procedures from A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy
Authors: Luraghi Paolo , Bigatto Viola , Cipriano Elia , Reato Gigliola , Orzan Francesca , Sassi Francesco , De Bacco Francesca , Isella Claudio , Bellomo Sara E. , Medico Enzo , Comoglio Paolo M. , Bertotti Andrea , Trusolino Livio , Boccaccio Carla
Published: April 2023

Extended Methods
Supplementary Methods from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

Detailed Materials and Methods
Figure S1 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Authors: Sandulache Vlad C. , Michikawa Chieko , Kataria Pranav , Gleber-Netto Frederico O. , Bell Diana , Trivedi Sanchit , Rao Xiayu , Wang Jing , Zhao Mei , Jasser Samar , Myers Jeffrey N. , Pickering Curtis R.
Published: April 2023

Figure S1 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Supplemental Table S7 from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Table S7. Reverse Phase Protein Array (RPPA) data. Total protein and phosphorylation levels in untreated and treated A673 and TC32 cells are normalized to total protein levels in each sample.
Supplemental Table S3 from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Table S3. Target sequences for shRNAs targeting AURKB expression in the in vivo dependency screen
Figure S4 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary Figure 4: Effect of ISTH1047 or ISTH0047 on glioma cell viability and clonogenic survival.
Figure S3 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary figure 3.ISTH1047 and ISTH0047 interfere with TGF-β signaling in a concentration-dependent manner
Figure S2 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary figure 2: Specificity of ISTH1047 or ISTH0047 to human and murine TGF-β1 or TGF-β2 sequences.
Supplementary Data from Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
Authors: Yu Lijian , Kim Haesook T. , Kasar Siddha N. , Benien Parul , Du Wei , Hoang Kevin , Aw Andrew , Tesar Bethany , Improgo Reina , Fernandes Stacey M. , Radhakrishnan Saranya , Klitgaard Josephine L. , Lee Charles , Getz Gad , Setlur Sunita R. , Brown Jennifer R.
Published: April 2023

Table S1. Minimally deleted regions (MDR) of recurrent deletions. Table S2. Clinical features of the patients in this study. Table S3. Overall survival is correlated with total copy number events and somatic mutations. Table S4. Details of the RPS15 mutations in this study. Figure S1. IGV Screen shot showing 17p deletions. Figure S2. Overview of CNAs in the tumor samples of 200 independent CLL patients. Figure S3. CNAs and somatic mutations in the 99 patients with both WES and SNP profiles. Figure S4. Analysis of TP53 and SF3B1 mutations. Figure S5. RPS15 mutations. Figure S6. GISTIC analysis discovered novel recurrent deletions in chromosomes 3p, 4p, 8p and 9p in del(17p) CLL. Figure S7. Associations of del(17p) and chromosomal deletions at 8p, 3p, 4p, and 9p. Figure S8. Overall survival in 17p patients with recurrent deletions. Figure S9. IGV screen shot showing 3p deletions. Figure S10. IGV screen shot showing 4p deletions. Figure S11. IGV screen shot showing 8p deletions. Figure S12. IGV screen shot showing 9p deletions. Figure S13. Association between CNAs and complex karyotype. Figure S14. Chromothripsis in del(17p) CLL samples. Figure S15. Sanger sequencing of TP53 with cnLOH at 17p.
Figure S1 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary figure 1: Structure of ISTH1047 and ISTH0047 antisense oligonucleotides.
Figure S7 from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
Authors: Wang Zheng , Hao Yajing , Zhang Chuanbao , Wang Zhiliang , Liu Xing , Li Guanzhang , Sun Lihua , Liang Jingshan , Luo Jianjun , Zhou Dabiao , Chen Runsheng , Jiang Tao
Published: April 2023

Cytomegalovirus infection in glioma (A) and survival analysis (B)
Figure S6 from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
Authors: Wang Zheng , Hao Yajing , Zhang Chuanbao , Wang Zhiliang , Liu Xing , Li Guanzhang , Sun Lihua , Liang Jingshan , Luo Jianjun , Zhou Dabiao , Chen Runsheng , Jiang Tao
Published: April 2023

SV40 (A) and WMSV (B) related GO terms in lower grade glioma
Figure S6 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Authors: Saha Dipongkor , Wakimoto Hiroaki , Peters Cole W. , Antoszczyk Slawomir J. , Rabkin Samuel D. , Martuza Robert L.
Published: April 2023

Figure S6 shows histopathology of treated mouse 005 GBM.
Figure S5 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Authors: Saha Dipongkor , Wakimoto Hiroaki , Peters Cole W. , Antoszczyk Slawomir J. , Rabkin Samuel D. , Martuza Robert L.
Published: April 2023

Figure S5 shows effects of axitinib on VEGFR and PDGFR signaling pathways in endothelial cells and MGG123 GBM cells.
Figure S4 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Authors: Saha Dipongkor , Wakimoto Hiroaki , Peters Cole W. , Antoszczyk Slawomir J. , Rabkin Samuel D. , Martuza Robert L.
Published: April 2023

Figure S4 shows immunohistochemical staining for cleaved caspase 3 and Sox2 in treated human MGG123 GBM
Figure S3 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Authors: Saha Dipongkor , Wakimoto Hiroaki , Peters Cole W. , Antoszczyk Slawomir J. , Rabkin Samuel D. , Martuza Robert L.
Published: April 2023

Figure S3 shows histopathology of treated human MGG123 GBM
Figure S1 from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
Authors: Wang Zheng , Hao Yajing , Zhang Chuanbao , Wang Zhiliang , Liu Xing , Li Guanzhang , Sun Lihua , Liang Jingshan , Luo Jianjun , Zhou Dabiao , Chen Runsheng , Jiang Tao
Published: April 2023

Survival analysis for HERV-K113
Figure S2 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Authors: Saha Dipongkor , Wakimoto Hiroaki , Peters Cole W. , Antoszczyk Slawomir J. , Rabkin Samuel D. , Martuza Robert L.
Published: April 2023

Figure S2 shows effects of axitnib and/or G47Î"-mIL12 on GBM stem-like population
Table S4 from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Authors: Greif Philipp A. , Hartmann Luise , Vosberg Sebastian , Stief Sophie M. , Mattes Raphael , Hellmann Ines , Metzeler Klaus H. , Herold Tobias , Bamopoulos Stefanos A. , Kerbs Paul , Jurinovic Vindi , Schumacher Daniela , Pastore Friederike , Bräundl Kathrin , Zellmeier Evelyn , Ksienzyk Bianka , Konstandin Nikola P. , Schneider Stephanie , Graf Alexander , Krebs Stefan , Blum Helmut , Neumann Martin , Baldus Claudia D. , Bohlander Stefan K. , Wolf Stephan , Görlich Dennis , Berdel Wolfgang E. , Wörmann Bernhard J. , Hiddemann Wolfgang , Spiekermann Karsten
Published: April 2023

Mutation profile of the cell lines MM-1 and MM-6
Table S3 from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Authors: Greif Philipp A. , Hartmann Luise , Vosberg Sebastian , Stief Sophie M. , Mattes Raphael , Hellmann Ines , Metzeler Klaus H. , Herold Tobias , Bamopoulos Stefanos A. , Kerbs Paul , Jurinovic Vindi , Schumacher Daniela , Pastore Friederike , Bräundl Kathrin , Zellmeier Evelyn , Ksienzyk Bianka , Konstandin Nikola P. , Schneider Stephanie , Graf Alexander , Krebs Stefan , Blum Helmut , Neumann Martin , Baldus Claudia D. , Bohlander Stefan K. , Wolf Stephan , Görlich Dennis , Berdel Wolfgang E. , Wörmann Bernhard J. , Hiddemann Wolfgang , Spiekermann Karsten
Published: April 2023

Somatic variants
Supplementary Table 3 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Authors: Magrangeas Florence , Kuiper Rowan , Avet-Loiseau Hervé , Gouraud Wilfried , Guérin-Charbonnel Catherine , Ferrer Ludovic , Aussem Alexandre , Elghazel Haytham , Suhard Jérôme , Der Sakissian Henri , Attal Michel , Munshi Nikhil C. , Sonneveld Pieter , Dumontet Charles , Moreau Philippe , van Duin Mark , Campion Loïc , Minvielle Stéphane
Published: April 2023

Supplementary Table 3: rs915854 functional annotations
Supplementary Table 2 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Authors: Magrangeas Florence , Kuiper Rowan , Avet-Loiseau Hervé , Gouraud Wilfried , Guérin-Charbonnel Catherine , Ferrer Ludovic , Aussem Alexandre , Elghazel Haytham , Suhard Jérôme , Der Sakissian Henri , Attal Michel , Munshi Nikhil C. , Sonneveld Pieter , Dumontet Charles , Moreau Philippe , van Duin Mark , Campion Loïc , Minvielle Stéphane
Published: April 2023

Supplementary Table 2: rs2839629 functional annotations
Table S2 from Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
Authors: Hanna Glenn J. , Busaidy Naifa L. , Chau Nicole G. , Wirth Lori J. , Barletta Justine A. , Calles Antonio , Haddad Robert I. , Kraft Stefan , Cabanillas Maria E. , Rabinowits Guilherme , O'Neill Anne , Limaye Sewanti A. , Alexander Erik K. , Moore Francis D. , Misiwkeiwicz Krystof , Thomas Tom , Nehs Matthew , Marqusee Ellen , Lee Stephanie L. , Jänne Pasi A. , Lorch Jochen H.
Published: April 2023

Supplementary Table S2. Clinical response and outcomes to everolimus in patients with advanced differentiated thyroid cancers by histologic subgroup
Supplementary Tables 2-4 from Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
Authors: Tan Yee Sun , Sansanaphongpricha Kanokwan , Xie Yuying , Donnelly Christopher R. , Luo Xiaobo , Heath Blake R. , Zhao Xinyi , Bellile Emily , Hu Hongxiang , Chen Hongwei , Polverini Peter J. , Chen Qianming , Young Simon , Carey Thomas E. , Nör Jacques E. , Ferris Robert L. , Wolf Gregory T. , Sun Duxin , Lei Yu L.
Published: April 2023

This file includes Supplementary Tables S2-S4 and captions for all supplementary tables.
Tale S1, S2, S4 from LncRNA–FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling
Authors: Bian Zehua , Zhang Jiwei , Li Min , Feng Yuyang , Wang Xue , Zhang Jia , Yao Surui , Jin Guoying , Du Jun , Han Weifeng , Yin Yuan , Huang Shenglin , Fei Bojian , Zou Jian , Huang Zhaohui
Published: April 2023

Tale S1, S2, S4
Figure S1-S11 from LncRNA–FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling
Authors: Bian Zehua , Zhang Jiwei , Li Min , Feng Yuyang , Wang Xue , Zhang Jia , Yao Surui , Jin Guoying , Du Jun , Han Weifeng , Yin Yuan , Huang Shenglin , Fei Bojian , Zou Jian , Huang Zhaohui
Published: April 2023

Figure S1-S11
Supplementary Tables from The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
Authors: Ricciardelli Carmela , Bianco-Miotto Tina , Jindal Shalini , Butler Lisa M. , Leung Samuel , McNeil Catriona M. , O'Toole Sandra A. , Ebrahimie Esmaeil , Millar Ewan K.A. , Sakko Andrew J. , Ruiz Alexandra I. , Vowler Sarah L. , Huntsman David G. , Birrell Stephen N. , Sutherland Robert L. , Palmieri Carlo , Hickey Theresa E. , Tilley Wayne D.
Published: April 2023

Supplementary Tables
Supplementary Figure Legends from The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
Authors: Ricciardelli Carmela , Bianco-Miotto Tina , Jindal Shalini , Butler Lisa M. , Leung Samuel , McNeil Catriona M. , O'Toole Sandra A. , Ebrahimie Esmaeil , Millar Ewan K.A. , Sakko Andrew J. , Ruiz Alexandra I. , Vowler Sarah L. , Huntsman David G. , Birrell Stephen N. , Sutherland Robert L. , Palmieri Carlo , Hickey Theresa E. , Tilley Wayne D.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure S5 from PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Authors: Yang Yinhui , Bai Yang , He Yundong , Zhao Yu , Chen Jiaxiang , Ma Linlin , Pan Yunqian , Hinten Michael , Zhang Jun , Karnes R. Jeffrey , Kohli Manish , Westendorf Jennifer J. , Li Benyi , Zhu Runzhi , Huang Haojie , Xu Wanhai
Published: April 2023

In panel A, FACS sorting plot shows the successful isolation of fibroblasts and macrophages with CD144a and F4/80 antibodies. In panel B, RT-qPCR analysis of fibroblast- (Pdgfrα) and immune cell-specific genes (Csf-1r) in cells isolated by anti-CD144a and F4/80 antibodies, respectively. Panel C shows IHC for Mmp9 in the prostate of Ptenpc-/- and Ptenpc-/-;Runx2+/- testicular feminized mice. In panel D, the diagram is shown to depict a hypothetical model involved in androgen synthesis within prostate tumor cells.
Supplementary Figure Legends from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Authors: Mercogliano María F. , De Martino Mara , Venturutti Leandro , Rivas Martín A. , Proietti Cecilia J. , Inurrigarro Gloria , Frahm Isabel , Allemand Daniel H. , Deza Ernesto Gil , Ares Sandra , Gercovich Felipe G. , Guzmán Pablo , Roa Juan C. , Elizalde Patricia V. , Schillaci Roxana
Published: April 2023

Supplementary Figure Legends
Supplementary Figure S2 from PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Authors: Yang Yinhui , Bai Yang , He Yundong , Zhao Yu , Chen Jiaxiang , Ma Linlin , Pan Yunqian , Hinten Michael , Zhang Jun , Karnes R. Jeffrey , Kohli Manish , Westendorf Jennifer J. , Li Benyi , Zhu Runzhi , Huang Haojie , Xu Wanhai
Published: April 2023

Panel A shows expression of endogenous RUNX2 proteins in C4-2B and LNCaP cell lines. Panel B and C show that treatment of LNCaP PCa cells with the PI3K inhibitor NVP-BEZ235 or the AKT inhibitor MK2206 downregulated expression of CYP11A1 and CYP17A1 mRNA. Panel D-H show the effect of RUNX2 knockdown, overexpression of constitutively active FOXO1 (FOXO1-A3), OCN knockdown, GPRC6A knockdown and ectopic expression of CREB on expression of CYP11A1 and CYP17A1 mRNA in LNCaP cells.
Supplementary Table 8 from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Table 8
Supplementary Table 4 from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Table 4
Supplementary Tables and Figures from Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Authors: Segal Neil H. , He Aiwu R. , Doi Toshihiko , Levy Ronald , Bhatia Shailender , Pishvaian Michael J. , Cesari Rossano , Chen Ying , Davis Craig B. , Huang Bo , Thall Aron D. , Gopal Ajay K.
Published: April 2023

Supplementary Table S1. Reason for treatment discontinuation Supplementary Table S2. Select laboratory abnormalities by maximum CTCAE grade Supplementary Table S3. Pharmacokinetic parameters for single-agent utomilumab (cycle 1) Supplementary Figure S1. Patient disposition. Supplementary Figure S2. Dose normalized Cmax of single-agent utomilumab in ADA-negative and ADA-positive patients (cycle 2, day 1). Supplementary Figure S3. Lymphocyte subpopulations assessed by flow cytometry over an 8-week (2-cycle) period following treatment with utomilumab.
Supplementary Figures 6 & 7 from A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy
Authors: Sayyid Rashid K. , Evans Andrew , Hersey Karen , Maloni Ranjena , Hurtado-Coll Antonio , Kulkarni Girish , Finelli Antonio , Zlotta Alexandre R. , Hamilton Robert , Gleave Martin , Fleshner Neil E.
Published: April 2023

Supplementary Figure 6. Comparison of intratumoral dihydrotestosterone (DHT) levels after treatment with degarelix, degarelix and bicalutamide, or LHRH agonist and bicalutamide. (ONLINE ONLY) Supplementary Figure 7. Comparison of intratumoral testosterone levels after treatment with degarelix, degarelix and bicalutamide, or LHRH agonist and bicalutamide. (ONLINE ONLY)